All In Biotech

Drug Trial Radar · NCT06825494

Clinical Studies for the Treatment of Advanced Solid Tumors

An Open-label Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab + Chemotherapy in Patients With Advanced Solid Tumors - Cohort A

Last checked: Nov 19, 2026Latest source record: Dec 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 194 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

194

Planned (sponsor's estimate)

Start

Apr 8, 2025

Primary completion

Mar 2026

Study completion Sep 2026

Sponsor

Sponsor type
Industry
First posted
Feb 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is part of a multicenter, open-label Phase Ib/II clinical study evaluating the efficacy, safety, and tolerability of LM-108 in combination with anti-tumor therapy in patients with advanced solid tumors. Phase Ib of Cohort A1 determines the dose of LM-108 in combination with penpulimab + oxaliplatin + capecitabine. Phase II explores the efficacy and safety of LM-108 in combination with anti-tumor therapy in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

  • LM-108 injection+Penpulimab+ Oxaliplatin+CapecitabineDrug

    LM-108 injection is a monoclonal antibody that selectively clears regulatory T cells that infiltrate tumor sites. Penpulimab is a novel and differentiated programmed cell death protein 1 (PD-1) monoclonal antibody. Oxaliplatin is a third-generation platinum drug. Capecitabine is a fluoropyrimidine.

  • Tislelizumab+Oxaliplatin+CapecitabineDrug

    Tislelizumab is a humanized monoclonal antibody against Programmed cell death -Ligand-1(PD-1). Oxaliplatin is a third-generation platinum drug. Capecitabine is a fluoropyrimidine.

  • LM-108 injection 10mg/kg +penpulimabDrug

    LM-108injection is a monoclonal antibody that selectively clears regulatory T cells that infiltrate tumor sites. Penpulimab is a novel and differentiated programmed cell death protein 1 (PD-1) monoclonal antibody.

  • LM-108 injection 600mg + penpulimabDrug

    LM-108 injection is a monoclonal antibody that selectively clears regulatory T cells that infiltrate tumor sites. Penpulimab is a novel and differentiated programmed cell death protein 1 (PD-1) monoclonal antibody.

  • enpulimab+ Oxaliplatin+CapecitabineDrug

    Penpulimab is a novel and differentiated programmed cell death protein 1 (PD-1) monoclonal antibody. Oxaliplatin is a third-generation platinum drug. Capecitabine is a fluoropyrimidine.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose limiting toxicity (DLT) eventsTime frame: From first dose to 21days after first dose
  2. Progression-free survival (PFS)Time frame: The estimated time from randomization to patient disease progression was 10 months

Locations

32 sites in 1 country. Site status is shown where the registry gives one.

  • Anhui Provincial Cancer Hospital

    Hefei, Anhui, China · Not yet recruiting

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, China · Not yet recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • The First Hospital of Lanzhou University

    Lanzhou, Gansu, China · Not yet recruiting

  • Gansu Wuwei Tumour Hospital

    Wuwei, Gansu, China · Not yet recruiting

  • Peking University Shenzhen Hospita

    Shenzhen, Guangdong, China · Not yet recruiting

  • Guangxi Medical University Cancer Hospital

    Nanning, Guangxi, China · Not yet recruiting

  • Tangshan People's Hospital

    Tangshan, Hebei, China · Not yet recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Not yet recruiting

  • Nanyang Second General Hospital

    Nanyang, Henan, China · Not yet recruiting

  • Ping mei shen ma Medical Group General Hospital

    Pingdingshan, Henan, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Not yet recruiting

  • Hubei Cancer Hospital

    Wuhan, Hubei, China · Not yet recruiting

  • The second xiangya hospital of central south university

    Changsha, Hunan, China · Not yet recruiting

  • Inner Mongolia Hospital of Peking University Cancer Hospita

    Hohhot, Inner Mongolia, China · Not yet recruiting

  • Jiangsu Provincial People's Hospital

    Nanjing, Jiangsu, China · Not yet recruiting

  • NanJing Drum Tower Hospital

    Nanjing, Jiangsu, China · Not yet recruiting

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China · Not yet recruiting

  • XuZhou Central Hospital

    Xuzhou, Jiangsu, China · Not yet recruiting

  • Jilin Cancer Hospital

    Changchun, Jilin, China · Not yet recruiting

  • The First Hospital Of China Medical University

    Shenyang, Liaoning, China · Not yet recruiting

  • The First Affiliated Hospital of Xi'an Jiaotong University Medical College

    Xi'an, Shaanxi, China · Not yet recruiting

  • Cancer Hospital of Shandong First Medical University

    Jinan, Shandong, China · Not yet recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Renji Hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • First Hospital of Shangxi Medical University

    Taiyuan, Shangxi, China · Not yet recruiting

  • Shanxi Cancer Hospital

    Taiyuan, Shanxi, China · Not yet recruiting

  • Sichuan Cancer Hospita

    Chengdu, Sichuan, China · Not yet recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China · Not yet recruiting

  • Xinjiang Medical University Affiliated Cancer Hospital

    Ürümqi, Xinjiang, China · Not yet recruiting

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.